Novo Nordisk to start late-stage trial of semaglutide to treat Alzheimer’s
COPENHAGEN (Reuters) – Diabetes drugmaker Novo Nordisk will start a late-stage clinical trial to test its semaglutide drug as a treatment for early Alzheimer’s disease, it said on Wednesday.
Novo shares were up 4.3% at 1418 GMT following the news.
Sydbank analyst Soeren Loentoft described the move as a “good signal”, showing Novo’s confidence in the drug, but warned developing treatments for Alzheimer’s was notoriously difficult.
“Many have tried without success in the last many years, so this is a high-risk study, and it is by no means certain that Novo’s semaglutide will have an effect,” he said.